Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis / Jong Yeob KIM in Autism Research, 15-2 (February 2022)  

Public ISBD [article]  inAutism Research > 15-2 (February 2022) . - p.340-352 Titre : Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis Type de document : texte imprimé Auteurs : Jong Yeob KIM, Auteur ; Min Je CHOI, Auteur ; Sungji HA, Auteur ; Jimin HWANG, Auteur ; Ai KOYANAGI, Auteur ; Elena DRAGIOTI, Auteur ; Joaquim RADUA, Auteur ; Leann SMITH, Auteur ; Louis JACOB, Auteur ; G.S. DE PABLO, Auteur ; Seung Won LEE, Auteur ; Dong Keon YON, Auteur ; Taylor THOMPSON, Auteur ; Samuele CORTESE, Auteur ; Gianluca LOLLO, Auteur ; Chih-Sung LIANG, Auteur ; Che-Sheng CHU, Auteur ; Paolo FUSAR-POLI, Auteur ; Keun-Ah CHEON, Auteur ; Jae Il SHIN, Auteur ; Marco SOLMI, Auteur Article en page(s) : p.340-352 Langues : Anglais (eng) Mots-clés : Crohn's disease  autism spectrum disorder  inflammatory bowel disease  meta-analysis  ulcerative colitis Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder (ASD) are frequently diagnosed with co-occurring medical conditions including inflammatory bowel disease (IBD). To investigate the association, we conducted a systematic review registered in PROSPERO (ID:CRD42021236263) with a random-effects meta-analysis. We searched PubMed, Embase, and PsycInfo (last search on January 25, 2021), and manually searched relevant publications. We included observational studies measuring the association between ASD and IBD. The primary outcome was the association (odds ratio, OR) between ASD and later development of IBD. Sensitivity analyses were conducted by quality, confounding adjustment, and study design. We performed meta-regression analyses and assessed heterogeneity, publication bias, and quality of studies with the Newcastle-Ottawa Scale. Overall, we included six studies consisting of eight datasets, including over 11 million participants. We found that ASD was significantly associated with subsequent incident IBD (any IBD, OR = 1.66, 95% confidence interval[CI] = 1.25-2.21, p < 0.001; ulcerative colitis, OR = 1.91, 95%CI = 1.41-2.6, p < 0.001; Crohn's disease, OR = 1.47, 95%CI = 1.15-1.88, p = 0.002). ASD and IBD were also associated regardless of temporal sequence of diagnosis (any IBD, OR = 1.57, 95%CI = 1.28-1.93, p < 0.001; ulcerative colitis, OR = 1.7, 95%CI = 1.36-2.12, p < 0.001; Crohn's disease, OR = 1.37, 95%CI = 1.12-1.69, p = 0.003). Sensitivity analyses confirmed the findings of the main analysis. Meta-regression did not identify any significant moderators. Publication bias was not detected. Quality was high in four datasets and medium in four. In conclusion, our findings highlight the need to screen for IBD in individuals with ASD, and future research should identify who, among those with ASD, has the highest risk of IBD, and elucidate the shared biological mechanisms between ASD and IBD. LAY SUMMARY: This systematic review and meta-analysis of eight observational datasets found that individuals with autism spectrum disorder (ASD) are more likely to develop any inflammatory bowel disease, ulcerative colitis, or Crohn's disease. Our findings highlight the need to screen for inflammatory bowel disease in patients with ASD and elucidate the shared biological mechanisms between the two disorders. En ligne : http://dx.doi.org/10.1002/aur.2656 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450 [article] Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis [texte imprimé] / Jong Yeob KIM, Auteur ; Min Je CHOI, Auteur ; Sungji HA, Auteur ; Jimin HWANG, Auteur ; Ai KOYANAGI, Auteur ; Elena DRAGIOTI, Auteur ; Joaquim RADUA, Auteur ; Leann SMITH, Auteur ; Louis JACOB, Auteur ; G.S. DE PABLO, Auteur ; Seung Won LEE, Auteur ; Dong Keon YON, Auteur ; Taylor THOMPSON, Auteur ; Samuele CORTESE, Auteur ; Gianluca LOLLO, Auteur ; Chih-Sung LIANG, Auteur ; Che-Sheng CHU, Auteur ; Paolo FUSAR-POLI, Auteur ; Keun-Ah CHEON, Auteur ; Jae Il SHIN, Auteur ; Marco SOLMI, Auteur . - p.340-352. Langues : Anglais (eng) in Autism Research > 15-2 (February 2022) . - p.340-352 Mots-clés : Crohn's disease  autism spectrum disorder  inflammatory bowel disease  meta-analysis  ulcerative colitis Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder (ASD) are frequently diagnosed with co-occurring medical conditions including inflammatory bowel disease (IBD). To investigate the association, we conducted a systematic review registered in PROSPERO (ID:CRD42021236263) with a random-effects meta-analysis. We searched PubMed, Embase, and PsycInfo (last search on January 25, 2021), and manually searched relevant publications. We included observational studies measuring the association between ASD and IBD. The primary outcome was the association (odds ratio, OR) between ASD and later development of IBD. Sensitivity analyses were conducted by quality, confounding adjustment, and study design. We performed meta-regression analyses and assessed heterogeneity, publication bias, and quality of studies with the Newcastle-Ottawa Scale. Overall, we included six studies consisting of eight datasets, including over 11 million participants. We found that ASD was significantly associated with subsequent incident IBD (any IBD, OR = 1.66, 95% confidence interval[CI] = 1.25-2.21, p < 0.001; ulcerative colitis, OR = 1.91, 95%CI = 1.41-2.6, p < 0.001; Crohn's disease, OR = 1.47, 95%CI = 1.15-1.88, p = 0.002). ASD and IBD were also associated regardless of temporal sequence of diagnosis (any IBD, OR = 1.57, 95%CI = 1.28-1.93, p < 0.001; ulcerative colitis, OR = 1.7, 95%CI = 1.36-2.12, p < 0.001; Crohn's disease, OR = 1.37, 95%CI = 1.12-1.69, p = 0.003). Sensitivity analyses confirmed the findings of the main analysis. Meta-regression did not identify any significant moderators. Publication bias was not detected. Quality was high in four datasets and medium in four. In conclusion, our findings highlight the need to screen for IBD in individuals with ASD, and future research should identify who, among those with ASD, has the highest risk of IBD, and elucidate the shared biological mechanisms between ASD and IBD. LAY SUMMARY: This systematic review and meta-analysis of eight observational datasets found that individuals with autism spectrum disorder (ASD) are more likely to develop any inflammatory bowel disease, ulcerative colitis, or Crohn's disease. Our findings highlight the need to screen for inflammatory bowel disease in patients with ASD and elucidate the shared biological mechanisms between the two disorders. En ligne : http://dx.doi.org/10.1002/aur.2656 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450

Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment / Hangnyoung CHOI in Molecular Autism, 15 (2024)  

Public ISBD [article]  inMolecular Autism > 15 (2024) . - 7p. Titre : Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment Type de document : texte imprimé Auteurs : Hangnyoung CHOI, Auteur ; Jae Han KIM, Auteur ; Hee Sang YANG, Auteur ; Jong Yeob KIM, Auteur ; Samuele CORTESE, Auteur ; Lee SMITH, Auteur ; Ai KOYANAGI, Auteur ; Elena DRAGIOTI, Auteur ; Joaquim RADUA, Auteur ; Paolo FUSAR-POLI, Auteur ; Jae Il SHIN, Auteur ; Keun-Ah CHEON, Auteur ; Marco SOLMI, Auteur Article en page(s) : 7p. Langues : Anglais (eng) Mots-clés : Male  Humans  Female  GRADE Approach  Aripiprazole  Risperidone  Autism Spectrum Disorder  Autism spectrum disorder  Irritability  Meta-analysis  Randomized controlled trial  Systematic review  ADHD. PFP received honoraria/has been a consultant for Angelini, Menarini,  Lundbeck, and Sunovion. MS received honoraria/has been a consultant for ABBVie,  Angelini, Lundbeck, and Otsuka. Index. décimale : PER Périodiques Résumé : BACKGROUND: Numerous interventions for irritability in autism spectrum disorder (ASD) have been investigated. We aimed to appraise the magnitude of pharmacological and non-pharmacological interventions for irritability in ASD without any restrictions in terms of eligible interventions. METHODS: We systematically searched PubMed/MEDLINE, Scopus, and Web of Science until April 15, 2023. We included randomized controlled trials (RCTs) with a parallel design that examined the efficacy of interventions for the treatment of irritability in patients of any age with ASD without any restrictions in terms of eligible interventions. We performed a random-effects meta-analysis by pooling effect sizes as Hedges' g. We classified assessed interventions as follows: pharmacological monotherapy, risperidone plus adjuvant therapy versus risperidone monotherapy, non-pharmacological intervention, and dietary intervention. We utilized the Cochrane tool to evaluate the risk of bias in each study and the GRADE approach to assess the certainty of evidence for each meta-analyzed intervention. RESULTS: Out of 5640 references, we identified 60 eligible articles with 45 different kinds of interventions, including 3531 participants, of which 80.9% were males (mean age [SD] = 8.79 [3.85]). For pharmacological monotherapy, risperidone (Hedges' g - 0.857, 95% CI - 1.263 to - 0.451, certainty of evidence: high) and aripiprazole (Hedges' g - 0.559, 95% CI - 0.767 to - 0.351, certainty of evidence: high) outperformed placebo. Among the non-pharmacological interventions, parent training (Hedges' g - 0.893, 95% CI - 1.184 to - 0.602, certainty of evidence: moderate) showed a significant result. None of the meta-analyzed interventions yielded significant effects among risperidone+adjuvant therapy and dietary supplementation. However, several novel molecules in augmentation to risperidone outperformed risperidone monotherapy, yet from one RCT each. LIMITATIONS: First, various tools have been utilized to measure the irritability in ASD, which may contribute to the heterogeneity of the outcomes. Second, meta-analyses for each intervention included only a small number of studies and participants. CONCLUSIONS: Only risperidone, aripiprazole among pharmacological interventions, and parent training among non-pharmacological interventions can be recommended for irritability in ASD. As an augmentation to risperidone, several novel treatments show promising effects, but further RCTs are needed to replicate findings. Trial registration PROSPERO, CRD42021243965. En ligne : https://dx.doi.org/10.1186/s13229-024-00585-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=538 [article] Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment [texte imprimé] / Hangnyoung CHOI, Auteur ; Jae Han KIM, Auteur ; Hee Sang YANG, Auteur ; Jong Yeob KIM, Auteur ; Samuele CORTESE, Auteur ; Lee SMITH, Auteur ; Ai KOYANAGI, Auteur ; Elena DRAGIOTI, Auteur ; Joaquim RADUA, Auteur ; Paolo FUSAR-POLI, Auteur ; Jae Il SHIN, Auteur ; Keun-Ah CHEON, Auteur ; Marco SOLMI, Auteur . - 7p. Langues : Anglais (eng) in Molecular Autism > 15 (2024) . - 7p. Mots-clés : Male  Humans  Female  GRADE Approach  Aripiprazole  Risperidone  Autism Spectrum Disorder  Autism spectrum disorder  Irritability  Meta-analysis  Randomized controlled trial  Systematic review  ADHD. PFP received honoraria/has been a consultant for Angelini, Menarini,  Lundbeck, and Sunovion. MS received honoraria/has been a consultant for ABBVie,  Angelini, Lundbeck, and Otsuka. Index. décimale : PER Périodiques Résumé : BACKGROUND: Numerous interventions for irritability in autism spectrum disorder (ASD) have been investigated. We aimed to appraise the magnitude of pharmacological and non-pharmacological interventions for irritability in ASD without any restrictions in terms of eligible interventions. METHODS: We systematically searched PubMed/MEDLINE, Scopus, and Web of Science until April 15, 2023. We included randomized controlled trials (RCTs) with a parallel design that examined the efficacy of interventions for the treatment of irritability in patients of any age with ASD without any restrictions in terms of eligible interventions. We performed a random-effects meta-analysis by pooling effect sizes as Hedges' g. We classified assessed interventions as follows: pharmacological monotherapy, risperidone plus adjuvant therapy versus risperidone monotherapy, non-pharmacological intervention, and dietary intervention. We utilized the Cochrane tool to evaluate the risk of bias in each study and the GRADE approach to assess the certainty of evidence for each meta-analyzed intervention. RESULTS: Out of 5640 references, we identified 60 eligible articles with 45 different kinds of interventions, including 3531 participants, of which 80.9% were males (mean age [SD] = 8.79 [3.85]). For pharmacological monotherapy, risperidone (Hedges' g - 0.857, 95% CI - 1.263 to - 0.451, certainty of evidence: high) and aripiprazole (Hedges' g - 0.559, 95% CI - 0.767 to - 0.351, certainty of evidence: high) outperformed placebo. Among the non-pharmacological interventions, parent training (Hedges' g - 0.893, 95% CI - 1.184 to - 0.602, certainty of evidence: moderate) showed a significant result. None of the meta-analyzed interventions yielded significant effects among risperidone+adjuvant therapy and dietary supplementation. However, several novel molecules in augmentation to risperidone outperformed risperidone monotherapy, yet from one RCT each. LIMITATIONS: First, various tools have been utilized to measure the irritability in ASD, which may contribute to the heterogeneity of the outcomes. Second, meta-analyses for each intervention included only a small number of studies and participants. CONCLUSIONS: Only risperidone, aripiprazole among pharmacological interventions, and parent training among non-pharmacological interventions can be recommended for irritability in ASD. As an augmentation to risperidone, several novel treatments show promising effects, but further RCTs are needed to replicate findings. Trial registration PROSPERO, CRD42021243965. En ligne : https://dx.doi.org/10.1186/s13229-024-00585-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=538

---

1 (1 - 2 / 2) Par page : 25 50 100 200